Ascendiant Capital Markets Lowers Alzamend Neuro (NASDAQ:ALZN) Price Target to $35.00

Alzamend Neuro (NASDAQ:ALZN) had its price objective decreased by Ascendiant Capital Markets from $50.00 to $35.00 in a research note released on Monday morning,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Alzamend Neuro Price Performance

Shares of Alzamend Neuro stock opened at $1.46 on Monday. Alzamend Neuro has a 12-month low of $1.40 and a 12-month high of $19.20. The company’s fifty day simple moving average is $1.68 and its two-hundred day simple moving average is $3.44.

Alzamend Neuro (NASDAQ:ALZN) last announced its earnings results on Wednesday, September 11th. The company reported ($1.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.38) by $1.13. As a group, equities analysts forecast that Alzamend Neuro will post -14.27 EPS for the current fiscal year.

Institutional Investors Weigh In On Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Virtu Financial LLC bought a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned approximately 0.38% of Alzamend Neuro at the end of the most recent quarter. 49.61% of the stock is currently owned by institutional investors.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.